European Leukemia Trial Registry
Trial: BERGAMO

More Details
Title Phase-II-Studie zu Bemcentinib bei Patienten mit MDS oder AML, die nicht auf die Standardtherapie ansprechen
Scientific Title A phase II study evaluating the efficacy and safety of bemcentinib in patients with MDS or AML failing standard of care therapy
Short Title BERGAMO
Trialgroup AML-Intergroup
Type of Trial single-group, prospective
Disease Myelodysplastic Syndrome(MDS) Intermedia II and high risk
Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Active
Start of Recruitment 01.01.2019
Leader Platzbecker, Prof. Dr. med., Uwe
Shortprotocol Shortprotocol
created 16.01.2019 Zenawit Krüger
changed 16.01.2019 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org